Who are S-1 plus Cisplatin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Placebo、CAPOX, FOLFOXIRI with bevacizumab, cetuximab + cisplatin + vinorelbine, cytarabine and mitoxantrone.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/s-1-plus-cisplatin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

S-1 plus Cisplatin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

S-1 plus Cisplatin (S-1 plus Cisplatin) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antineoplastic agents. Area: Oncology.

phase 3 Antineoplastic agents Thymidylate synthase, DNA Oncology Small molecule Live · refreshed every 30 min

Target snapshot

S-1 plus Cisplatin (S-1 plus Cisplatin) — Taiho Pharmaceutical Co., Ltd.. S-1 is a fluoropyrimidine derivative that inhibits thymidylate synthase, while cisplatin is a platinum-based alkylating agent that cross-links DNA, thereby inhibiting DNA replication and transcription.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
S-1 plus Cisplatin TARGET	S-1 plus Cisplatin	Taiho Pharmaceutical Co., Ltd.	phase 3	Antineoplastic agents	Thymidylate synthase, DNA
Placebo、CAPOX	Placebo、CAPOX	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	phase 3	chemotherapy regimen	thymidylate synthase, DNA repair enzymes
FOLFOXIRI with bevacizumab	FOLFOXIRI with bevacizumab	Dutch Colorectal Cancer Group	phase 3	Chemotherapy combination with anti-angiogenic monoclonal antibody	VEGF (bevacizumab component); topoisomerase I, thymidylate synthase, DNA (FOLFOXIRI components)
cetuximab + cisplatin + vinorelbine	cetuximab + cisplatin + vinorelbine	Merck KGaA, Darmstadt, Germany	phase 3	Antineoplastic agents	EGFR
cytarabine and mitoxantrone	cytarabine and mitoxantrone	Pfizer	phase 3	Antineoplastic agents

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antineoplastic agents class)

Asan Medical Center · 1 drug in this class
Central European Cooperative Oncology Group · 1 drug in this class
Croatian Cooperative Group for Clinical Research in Oncology · 1 drug in this class
Eli Lilly and Company · 1 drug in this class
Groupe Oncologie Radiotherapie Tete et Cou · 1 drug in this class
Merck KGaA, Darmstadt, Germany · 1 drug in this class
Pfizer · 1 drug in this class
Taiho Pharmaceutical Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). S-1 plus Cisplatin — Competitive Intelligence Brief. https://druglandscape.com/ci/s-1-plus-cisplatin. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing